IPP Bureau
AstraZeneca’s new R&D Centre and Alexion HQ in Cambridge, Massachusetts
By IPP Bureau - May 01, 2022
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Global Cord Blood Corp acquires Cellenkos to advance cell therapy market
By IPP Bureau - May 01, 2022
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Inmagene receives USFDA's IND clearance for ox40 antagonist
By IPP Bureau - May 01, 2022
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Genome Insight draws US $ 23 million in Series B Funding
By IPP Bureau - May 01, 2022
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
BeiGene to open new site at Princeton, New Jersey
By IPP Bureau - May 01, 2022
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
India’s pharma exports grow by 103% since 2013-14
By IPP Bureau - May 01, 2022
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis
By IPP Bureau - May 01, 2022
It affects up to 10 per cent of women of reproductive age around the world
GeneStore launches Centre of Excellence in Gurugram, India
By IPP Bureau - May 01, 2022
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
By IPP Bureau - April 29, 2022
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Ultomiris approved in the US for adults with generalised myasthenia gravis
By IPP Bureau - April 29, 2022
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Moderna files for authorization of its Covid-19 vaccine in young children six months to six years
By IPP Bureau - April 29, 2022
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Philips and Prisma Health sign multi-year, long-term strategic partnership
By IPP Bureau - April 29, 2022
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
By IPP Bureau - April 29, 2022
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
By IPP Bureau - April 29, 2022
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
AstraZeneca expands its ‘Young Health Program’ in Delhi
By IPP Bureau - April 29, 2022
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
